• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

• 药品评价-临床研究 • 上一篇    下一篇

左炔诺孕酮缓释系统联合米非司酮治疗子宫腺肌病的临床疗效观察

卞晓阳   

  1. 原阳县人民医院
  • 收稿日期:2017-11-15 修回日期:2017-11-15 出版日期:2018-04-25 发布日期:2018-04-25

Clinical Efficacy of Levonorgestrel Releasing System and Mifepristone in Treatment of Adenomyosis

bianxiaoyang   

  1. Yuanyang country people's hospital
  • Received:2017-11-15 Revised:2017-11-15 Online:2018-04-25 Published:2018-04-25

摘要: [摘要] 目的 观察左炔诺孕酮缓释系统联合米非司酮治疗子宫腺肌病的临床疗效。方法 选取我院2016年1月至2017年3月治疗的子宫腺肌病患者116例为研究对象,按照随机数表法将其分为两组,各58例。对照组给予左炔诺孕酮缓释系统治疗,观察组在对照组治疗同时联合米非司酮治疗。比较两组临床症状改善、血清CA125、性激素、子宫改善及不良反应。结果 治疗后对照组月经期、PBCA、VAS评分均比观察组高,差异有统计学意义(P<0.05);治疗后血清CA125、LH、E2、FSH水平均比观察组高,差异有统计学意义(P<0.05);两组均未出现明显不良反应。结论 左炔诺孕酮缓释系统联合米非司酮治疗可有效降低子宫腺肌病患者血清CA125及性激素水平,利于患者临床症状的改善,缓解痛经情况,且用药安全可靠。

Abstract: Objective:To observe the clinical efficacy of levonorgestrel releasing system and mifepristone in treatment of adenomyosis.Methods: 116 patients with adenomyosis treated from January 2016 to March 2017 were selected, and they were divided into two groups by random number table, 58 cases in each group.Control group was given levonorgestrel releasing system, while observation group was treated with mifepristone.The improvement of clinical symptoms, CA125, sex hormone, uterine improvement and adverse reactions were compared between the two groups.Results:After treatment, the menstrual phase, PBCA, VAS scores of control group were higher than those of observation group (P<0.05). After treatment, the levels of CA125, LH, E2, FSH in control group were higher than those in observation group (P<0.05). There were no obvious adverse reactions in two groups.Conclusion:Levonorgestrel releasing system and mifepristone in treatment of adenomyosis can decrease the levels of CA125 and sex hormone, improve clinical symptoms, relieve dysmenorrhea, which is safe and reliable.